DW18343
Pre-clinical- Indications
- Cancer, Non-small cell lung cancer, Melanoma, Renal cancer, Colon cancer, Breast cancer
Company intelligence / Profile preview
Wayen Biotechnologies Inc.
Shanghai, Shanghai, Chinapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Provides high-quality extracellular vesicle proteomics services, Luminex liquid suspension chip services, signal pathway phosphorylation antibody chips, and SPR molecular interaction technology services
- Industry
- Drug Discovery Services
02
Drug pipeline
1 asset03
Partnerships
RayBiotechCDI Labs
Beyond the preview
Go deeper on Wayen Biotechnologies Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Wayen Biotechnologies Inc..